Compare ARMOUR Residential REIT, Inc. (ARR) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs ClearPoint Neuro Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $17.09 (market cap $2.11B), while ClearPoint Neuro Inc trades at $17.19 (market cap $524.82M). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 4× ClearPoint Neuro Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 16.89% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| ARR | CLPT | |
|---|---|---|
Market Cap | $2.11B | $524.82M |
Sector | Financials | Health |
52-Week High | $19.12 | $29.60 |
52-Week Low | $14.05 | $8.66 |
Dividend Yield | 16.89% | — |
Enterprise Value | — | $552.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $17.05, down 0.23% today, with a neutral technical signal and bullish moving averages. The stock shows a low P/E of 6.85 and P/B of 0.9, indicating potential undervaluation, while recent earnings beat expectations in Q1 2026. Dividend payments remain steady at $0.24 per share, supporting income appeal. Revenue for 2025 was $332M with a net income margin of 97.2%, though cash flow trends show volatility in investing activities.
Outlook is mixed: analyst consensus is a $18.50 price target with 20% buy ratings, but risks include volatile earnings and high cash flow swings. The stock offers value and yield, yet requires caution due to operational inconsistencies and market sentiment leaning hold.
ClearPoint Neuro (CLPT) trades at $17.50, down 2.13% on the day, with a bullish technical signal from moving averages despite recent earnings misses. The company reported record Q1 2026 revenue of $41M with 43% growth but continues to post significant net losses, reflected in a negative net income margin of -71.57%. Recent FDA clearance for its Velocity Alpha surgical drill and a new partnership in South Korea highlight ongoing business development efforts.
The investment case hinges on CLPT's positioning in the gene therapy enabling space, with 100% analyst buy ratings supporting long-term growth potential. However, persistent cash burn, regulatory dependencies on partner therapies like AMT-130, and execution risks present substantial challenges. Investors face high volatility given the speculative nature of its growth trajectory against current profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
